Single-use Bioreactor Market is witnessing a high CAGR growth of 21.0% by 2027

Global Single-use Bioreactor Market is witnessing a high CAGR growth of 21.0% and is expected to reach USD 12.4 Bn by 2027.

The Global Single-use Bioreactor Market is growing significantly due to increasing its use in bioprocessing industries, rising geriatric population, and growing incidence of chronic diseases such as cancer. Moreover, growing R&D expenditure by industries, strong government support in terms of funding for research infrastructure and rising adoption of disposable technology in pharmaceutical and biopharmaceutical ecosystems are expected to leverage the demand of the ecosystem during forecast period. In addition, frequent launch of products and rising number of patents expiration is expected to boost the growth of single-use bioreactor demand during forecast period. However, inflated cost of products and lack of skilled professionals are expected to hinder the growth of single-use bioreactor demand during the forecast period.

Moreover, rising use of single-use bioreactors in various domains of pharmaceutical industry such as drug development, vaccine development, excipient validation, and clinical trials is expected to trigger the growth of single-use bioreactor demand during the forecast period. Besides this, upsurge for biosimilar production in the US market and growing demand for personalized medicines are expected to create significant growth opportunities for single-use bioreactor demand during the forecast period. Single-use bioreactors have limited application in animal cell cultures wherein the oxygen supply & heat loads are low and continuous mixing is not required. Moreover, disposable bioreactor is being alternatively adopted for new drug development by biotechnology industries for small-to-medium quantities of antibodies, vaccines, viruses, and therapeutic proteins.

Covid-19 pandemic has affected the supply chain of pharmaceutical products across the globe. The restrictions on manufacturing process and exporting of products in countries such as Europe, the U.S have promptly declined due to covid-19 spread. On the contrary, pharmaceutical and biopharmaceutical companies started focusing and investing in the development of therapy against coronavirus by using single-use bioreactor for speed and flexibility by reducing other operating expenditure. Thus, single-use bioreactor played a key role during covid-19 and thus creating growth opportunities of market players during the forecast period.

Global Single-use Bioreactor Market by Region Outlook (Revenue, USD Million, 2021-2027)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Based on region, Asia-Pacific market is expected to witness the highest growth during the forecast period due to rising number of manufacturing units and growing biopharmaceutical R&D. Moreover, reduction in automation complexity, emerging biologics market, and rising applications of single-use bioreactors in marine cultivation process are expected to boost the growth of single-use bioreactor demand in this region during the forecast period.  

The Global Single-use Bioreactor Market Segmentation:

Global Single-use Bioreactor Market by Product Type Outlook (Revenue, USD Million, 2021-2027)

• Single-use Bioreactor System
• Single-use Filtration Assemblies
• Single-use Media Bags
• Others

Global Single-use Bioreactor Market by Type Outlook (Revenue, USD Million, 2021-2027)

• Wave-Induced
• Stirred- Tank
• Bubble-Column

Global Single-use Bioreactor Market by Cell Type Outlook (Revenue, USD Million, 2021-2027)

• Bacterial Cells
• Mammalian Cells
• Yeast Cells
• Others

Global Single-use Bioreactor Market by Molecule Type Outlook (Revenue, USD Million, 2021-2027)

• Vaccines
• Monoclonal Antibodies
• Stem Cells
• Gene-Modified Cells
• Others

Global Single-use Bioreactor Market by Applications Outlook (Revenue, USD Million, 2021-2027)

• Process Development
• Research and Development
• Bioproduction

Key Findings:

• Based on product, single-use bioreactor segment is expected to hold the largest market share during forecast period
• Based on type, stirred-tank segment is expected to dominate the market during forecast period
• Based on cell type, mammalian cells segment is expected to contribute highest to the market during forecast period
• Based on molecule type, monoclonal antibodies held largest market share in 2020 and is expected to increase more during the forecast period
• Based on applications, process development is expected to witness fastest growth during the forecast period
• Based on region, North America is expected to hold the largest market share during the forecast period. On the contrary, Asia-Pacific is expected to witness highest growth during forecast period.

Company Profiles and Competitive Intelligence

The key players operating in the single-use bioreactor market are:

• Sartorius Stedim Biotech
• Thermo Fisher Scientific
• Danaher Corporation
• Merck KGaA
• Getinge AB
• Eppendorf AG
• CESCO Bioengineering
• Cellexus
• PBS Biotech Inc.
• Distek Inc.
• ABEC Able Corporation & Biott Corporation
• G&G Technologies Inc.
• Solida Biotech GmBH
• Satake Chemical Equipment Mfg., Ltd
• Stobbe Pharma GmBH
• Others
• Celltainer Biotech BV
• Meissner Filtration Products Inc.
• bbi-biotech GmBH
• ENDEL ENGIE
• OmniBRx biotechnologies
• New Horizon Biotechnology Inc.
• GPC Bio
• Cell culture company
• Aptus bioreactors

Recent News:

• In February 2021, WuXi Biologics announced that its MFG5 Drug Substance manufacturing unit in China has introduced single-use bioreactor with the capacity of 36,000L, deploying nine 4,000L bioreactor. Leveraging the state-of-the-art design, MFG5 is expected to provide high-quality and flexible manufacturing solutions that would cater to the needs of the customer. This launch of a single-use bioreactor is expected to expand the product portfolio of the company.
• In February 2020, MabPlex International introduced additional operations with the two cell culture production lines with GE brand of 2000-liter single-use bioreactor devices. With this addition, the company expects to diversify and expand their portfolio by using Sartorius brand 2,000 L single-use bioreactors.